Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Equator Therapeutics General Information
Developing drugs that pharmacologically stimulate thermogenesis to achieve sustained weight loss by targeting mitochondria to generate heat, which has been proven to reverse obesity and type 2 diabetes in animal models
Contact Information
Primary Industry
Biotech
Corporate Office
San Francisco, California
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
Equator Therapeutics Funding
No funding data available
To view Equator Therapeutics's complete valuation and funding history, request access »